Total
0
Shares
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka
Managing Director, Dr Rajen Manicka
Sourced: The Edge Markets
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Natural wellness company Holista CollTech (HCT) has filed a global patent for its Natshield nasal sanitising balm
  • The balm contains the active ingredient Path-Away, which has been proven to be an effective sanitiser against many viruses, bacteria and fungi
  • Tests carried out by a U.K. bio-safety lab also found Path-Away to be 99.99 per cent effective against the feline coronavirus, a surrogate of COVID-19
  • Holista CollTech expects the patent to be granted in 12 to 18 months but plans to commercialise Natshield later this year under patent pending protection
  • Company shares are up 5.9 per cent and trading for 18 cents each

Natural wellness company Holista CollTech (HCT) has filed a global patent for its Natshield nasal sanitising balm.

The balm contains the active ingredient Path-Away, developed by Global Infection Control Consultants, which has been proven to be an effective sanitiser against many viruses, bacteria and fungi.

In April, tests carried out by a U.K. bio-safety laboratory found Path-Away to be 99.99 per cent effective against the feline coronavirus, a surrogate of the COVID-19 novel coronavirus.

Holista CollTech bottles and distributes sanitisers containing Path-Away under its Natshield brand. In January, it sold out of Natshield sanitisers as global demand for sanitisers and disinfectants spiked with the emergence of the novel coronavirus.

In February, the company partnered with Global Infection Control Consultants to co-develop a nasal sanitising balm that would incorporate Path-Away.

The nose is an easy entry point for viruses due to it being warm, dark, damp and rich in fatty acids and amino acids and leading directly to the sinuses, throat and lungs.

According to Holista CollTech, the Natshield nasal balm will offer up to six hours of protection from viruses, be non-irritating and safe if accidentally swallowed.

Initially, the company had planned to file the patent application in March, however, this was delayed mostly due to lockdowns in Australia, the United States and Malaysia, where the balm is being co-developed.

Holist CollTech expects the patent could be granted in 12 to 18 months but plans to commercialise the Natshield nasal balm earlier under ‘patent-pending’ protection.

The company intends to launch the product by the third quarter of 2020, prior to the northern hemisphere winter and flu season.

Holista CollTech shares are up 5.9 per cent and trading for 18 cents each at 2:25 pm AEST.

HCT by the numbers
More From The Market Herald
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.